SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio-Chem Pharma (BCHXF)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jbershad who wrote (8)8/14/1996 1:30:00 AM
From: Adrian Wu   of 43
 
jbershad: Sorry, I must have missed your earlier post. Sometimes, I have several messages at once and sometimes never got round to responding to all of them. You are correct. I in fact looked theough the papers and did find some with triple and double therapy showing impressive reductions in viral burden. I in fact attende a teleconference on HIV drig therapy recently and saw some additional data with AZT and Norvir. I think there is definitly a place for viral load testing (PCR or branch DNA assays) in patients with even high CD4 counts since CD4 counts do not predict disease progression to the same extent. With this data on hand, physicians will be much more willing to start patients on drug therapy early, and the benefits will be much greater.
I would certainly not contemplate using single agent for therapy nowadays because resistance develop too quickly. A rational approach would be to use AZT + 3TC or AZT + protease inhibitor. AZT will remain the mainstay since it's toxicities are well understood. Whether 3TC will be able to duke it out with the numerous PIs coming into the market as the second agent still remains to be seen, and in practice, three drug therapy is impracticle because of cost and compliance issues.

Good luck,

Adrian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News